California State Teachers Retirement System acquired a new position in Dova Pharmaceuticals Inc (NASDAQ:DOVA) in the third quarter, HoldingsChannel reports. The firm acquired 8,300 shares of the company’s stock, valued at approximately $202,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. purchased a new stake in Dova Pharmaceuticals during the 3rd quarter valued at about $241,000. Bank of New York Mellon Corp purchased a new stake in Dova Pharmaceuticals during the 3rd quarter valued at about $340,000. JPMorgan Chase & Co. purchased a new stake in Dova Pharmaceuticals during the 2nd quarter valued at about $382,000. Vanguard Group Inc. purchased a new stake in Dova Pharmaceuticals during the 2nd quarter valued at about $390,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Dova Pharmaceuticals during the 2nd quarter valued at about $493,000. Hedge funds and other institutional investors own 26.20% of the company’s stock.
Several brokerages recently weighed in on DOVA. Jefferies Group increased their target price on Dova Pharmaceuticals to $33.00 and gave the company a “buy” rating in a report on Tuesday, November 28th. BidaskClub cut Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, January 5th. Finally, Zacks Investment Research cut Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $32.75.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). During the same quarter last year, the company earned ($0.41) earnings per share. sell-side analysts forecast that Dova Pharmaceuticals Inc will post -1.51 EPS for the current year.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.